Mirum Pharmaceuticals, Inc. (MIRM)
96.72
+0.41
(+0.43%)
USD |
NASDAQ |
Aug 24, 16:00
96.74
+0.02
(+0.03%)
After-Hours: 20:00
Mirum Pharmaceuticals Gross Profit Margin (Quarterly) : 82.65% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 82.65% |
| March 31, 2026 | 81.94% |
| December 31, 2025 | 80.97% |
| September 30, 2025 | 80.75% |
| June 30, 2025 | 81.55% |
| March 31, 2025 | 79.33% |
| December 31, 2024 | 77.03% |
| September 30, 2024 | 76.81% |
| June 30, 2024 | 73.83% |
| March 31, 2024 | 74.01% |
| December 31, 2023 | 67.50% |
| Date | Value |
|---|---|
| September 30, 2023 | 78.44% |
| June 30, 2023 | 81.74% |
| March 31, 2023 | 84.13% |
| December 31, 2022 | 83.53% |
| September 30, 2022 | 83.88% |
| June 30, 2022 | 85.00% |
| March 31, 2022 | 80.87% |
| December 31, 2021 | 36.74% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Incyte Corp. | 92.57% |
| Insmed, Inc. | 83.71% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| BioMarin Pharmaceutical, Inc. | 72.27% |
| Ionis Pharmaceuticals, Inc. | 96.13% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -393.2% |
| Return on Assets | -100.3% |
| Return on Invested Capital | -137.1% |
| Profit Margin (Quarterly) | -38.14% |
| Operating Margin (Quarterly) | -14.81% |
| Return on Net Operating Assets | -211.8% |